FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914252445> ?p ?o ?g. }

• W2914252445 abstract "Vinorelbine has demonstrated anticancer activity and is primarily metabolized in the liver. This single-institution, phase I pilot study describes the safety and pharmacokinetics of vinorelbine in patients with varying degrees of hepatic impairment.Patients with treatment-refractory solid tumors were enrolled into treatment arms based on vinorelbine dose (weekly infusions of 7.5-30 mg/m2) and liver function (normal liver function, mild, moderate, or severe liver dysfunction). Vinorelbine pharmacokinetics were evaluated to describe its relationship with liver function. Indocyanine green (ICG) clearance was assessed for correlation with pharmacokinetics.Forty-seven patients were enrolled, and a total of 108 grade 3-4 treatment-related adverse events (AEs) occurred. Of these, grade 3-4 myelosuppression was the most common (34.3%). Thirty-three (30.6%), 22 (20.4%), and 9 (8.3%) grade 3-4 AEs were observed in the vinorelbine 20 mg/m2/severe, 15 mg/m2/moderate, and 7.5 mg/m2/severe liver dysfunction groups, respectively, with the majority being nonhematologic toxicities. ICG clearance decreased as liver function worsened. Vinorelbine pharmacokinetics were not correlated with ICG elimination or the degree of liver dysfunction.For patients with severe liver dysfunction (bilirubin >3.0 mg/dL), vinorelbine doses ≥7.5 mg/m2 are poorly tolerated. The high incidence of grade 3-4 AEs with 15 mg/m2 vinorelbine in moderate liver dysfunction (bilirubin 1.5-3.0 mg/dL) raises concerns for its safety in this population. Vinorelbine pharmacokinetics are not affected by liver dysfunction; however, levels of the active metabolite 4-O-deacetylvinorelbine were not measured and may be higher in patients with liver dysfunction if its elimination is impacted by liver impairment to a greater degree than the parent drug.Vinorelbine remains widely prescribed in advanced malignancies and is under development in immunotherapy combinations. Given vinorelbine is primarily hepatically metabolized, understanding its safety and pharmacokinetics in liver dysfunction remains paramount. In this phase I pilot study, weekly vinorelbine at doses ≥7.5 mg/m2 is poorly tolerated in those with severe liver dysfunction. Furthermore, a high incidence of grade 3-4 toxicities was observed with vinorelbine at 15 mg/m2 in those with moderate liver dysfunction. Vinorelbine pharmacokinetics do not appear affected by degree of liver dysfunction. Further evaluation of levels of the free drug and active metabolites in relationship to liver function are warranted." @default.
• W2914252445 created "2019-02-21" @default.
• W2914252445 creator A5000500580 @default.
• W2914252445 creator A5006089136 @default.
• W2914252445 creator A5009303158 @default.
• W2914252445 creator A5014173403 @default.
• W2914252445 creator A5022022603 @default.
• W2914252445 creator A5058936977 @default.
• W2914252445 creator A5080105357 @default.
• W2914252445 creator A5082853715 @default.
• W2914252445 creator A5084571872 @default.
• W2914252445 creator A5087409546 @default.
• W2914252445 date "2019-02-01" @default.
• W2914252445 modified "2023-09-27" @default.
• W2914252445 title "A Pilot Study of Vinorelbine Safety and Pharmacokinetics in Patients with Varying Degrees of Liver Dysfunction" @default.
• W2914252445 cites W1513454013 @default.
• W2914252445 cites W1516737592 @default.
• W2914252445 cites W1971579914 @default.
• W2914252445 cites W1990277537 @default.
• W2914252445 cites W1991199427 @default.
• W2914252445 cites W2036026512 @default.
• W2914252445 cites W2053991217 @default.
• W2914252445 cites W2055445152 @default.
• W2914252445 cites W2085566855 @default.
• W2914252445 cites W2089618673 @default.
• W2914252445 cites W2112776466 @default.
• W2914252445 cites W2129793485 @default.
• W2914252445 cites W2261464614 @default.
• W2914252445 cites W2313543080 @default.
• W2914252445 cites W349943987 @default.
• W2914252445 cites W4250769897 @default.
• W2914252445 cites W949413916 @default.
• W2914252445 cites W98090258 @default.
• W2914252445 doi "https://doi.org/10.1634/theoncologist.2018-0336" @default.
• W2914252445 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6693729" @default.
• W2914252445 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30710067" @default.
• W2914252445 hasPublicationYear "2019" @default.
• W2914252445 type Work @default.
• W2914252445 sameAs 2914252445 @default.
• W2914252445 citedByCount "1" @default.
• W2914252445 countsByYear W29142524452019 @default.
• W2914252445 crossrefType "journal-article" @default.
• W2914252445 hasAuthorship W2914252445A5000500580 @default.
• W2914252445 hasAuthorship W2914252445A5006089136 @default.
• W2914252445 hasAuthorship W2914252445A5009303158 @default.
• W2914252445 hasAuthorship W2914252445A5014173403 @default.
• W2914252445 hasAuthorship W2914252445A5022022603 @default.
• W2914252445 hasAuthorship W2914252445A5058936977 @default.
• W2914252445 hasAuthorship W2914252445A5080105357 @default.
• W2914252445 hasAuthorship W2914252445A5082853715 @default.
• W2914252445 hasAuthorship W2914252445A5084571872 @default.
• W2914252445 hasAuthorship W2914252445A5087409546 @default.
• W2914252445 hasBestOaLocation W29142524452 @default.
• W2914252445 hasConcept C112705442 @default.
• W2914252445 hasConcept C126322002 @default.
• W2914252445 hasConcept C197934379 @default.
• W2914252445 hasConcept C2776694085 @default.
• W2914252445 hasConcept C2777513400 @default.
• W2914252445 hasConcept C2778239845 @default.
• W2914252445 hasConcept C2780350996 @default.
• W2914252445 hasConcept C2908647359 @default.
• W2914252445 hasConcept C2992208098 @default.
• W2914252445 hasConcept C512861765 @default.
• W2914252445 hasConcept C71924100 @default.
• W2914252445 hasConcept C90924648 @default.
• W2914252445 hasConcept C98274493 @default.
• W2914252445 hasConcept C99454951 @default.
• W2914252445 hasConceptScore W2914252445C112705442 @default.
• W2914252445 hasConceptScore W2914252445C126322002 @default.
• W2914252445 hasConceptScore W2914252445C197934379 @default.
• W2914252445 hasConceptScore W2914252445C2776694085 @default.
• W2914252445 hasConceptScore W2914252445C2777513400 @default.
• W2914252445 hasConceptScore W2914252445C2778239845 @default.
• W2914252445 hasConceptScore W2914252445C2780350996 @default.
• W2914252445 hasConceptScore W2914252445C2908647359 @default.
• W2914252445 hasConceptScore W2914252445C2992208098 @default.
• W2914252445 hasConceptScore W2914252445C512861765 @default.
• W2914252445 hasConceptScore W2914252445C71924100 @default.
• W2914252445 hasConceptScore W2914252445C90924648 @default.
• W2914252445 hasConceptScore W2914252445C98274493 @default.
• W2914252445 hasConceptScore W2914252445C99454951 @default.
• W2914252445 hasFunder F4320332161 @default.
• W2914252445 hasFunder F4320337351 @default.
• W2914252445 hasLocation W29142524451 @default.
• W2914252445 hasLocation W29142524452 @default.
• W2914252445 hasLocation W29142524453 @default.
• W2914252445 hasLocation W29142524454 @default.
• W2914252445 hasOpenAccess W2914252445 @default.
• W2914252445 hasPrimaryLocation W29142524451 @default.
• W2914252445 hasRelatedWork W129680564 @default.
• W2914252445 hasRelatedWork W2120918830 @default.
• W2914252445 hasRelatedWork W2349687627 @default.
• W2914252445 hasRelatedWork W2351452419 @default.
• W2914252445 hasRelatedWork W2367455770 @default.
• W2914252445 hasRelatedWork W2379416335 @default.
• W2914252445 hasRelatedWork W2388710643 @default.
• W2914252445 hasRelatedWork W2414506539 @default.
• W2914252445 hasRelatedWork W2469352269 @default.
• W2914252445 hasRelatedWork W3030708540 @default.
• W2914252445 isParatext "false" @default.

• next